OBJECTIVE： To study the improvement effects of Rouganbao granules on liver fibrosis of model rats， and to provide experimental evidence for further development of this preparation. METHODS： Totally 45 male SD rats were divided into normal group， model group， positive control group （Fuzheng huayu capsules， 0.4 g/kg） and Rouganbao granules high-dose and low-dose groups （16.8， 8.4 g/kg by crude drug） according to random number table， with 9 rats in each group. Except for normal group， other groups were given CCl4 subcutaneously and high lipid diet+15％ ethanol solution for 12 weeks to establish liver fibrosis model. After modeling， medication groups were given relevant medicine intragastrically， once a day， for consecutive 12 weeks. Normal group and model group were given corresponding volume of water intragastrically. The pathology change of liver tissues of rats was observed by inverted microscope. The levels of liver function indexes （ALT， AST， ALB） and liver fibrosis indexes （HA， Ⅳ-C， LN， Ⅲ-PC） were determined by ELISA. RESULTS： Compared with model group， liver cell vacuolation and liver fibrosis of rats were improved significantly in Rouganbao granule high-dose and low-dose groups； central vein was clearly visible， and no dilation and atrophy were found， especially in high-dose group； the serum levels of ALT and AST were decreased significantly， while the level of ALB was increased significantly （P＜0.05 or P＜0.01）， of which the protective effect for liver was similar to positive control drug but better in increasing ALB （P＜0.05 or P＜0.01）； the serum levels of HA， Ⅳ-C， LN and Ⅲ-PC were all decreased in varying degree， especially in high-dose group （P＜0.05 or P＜0.01）， of which the effect of relieving liver fibrosis was similar to positive control drug. CONCLUSIONS： Rouganbao granules can improve liver function and delay the progression of liver fibrosis in model rats.